PATENT CLAIM ANALYSIS

Application Number: 15779609
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-12
Patent Classification: ["514", "171000"]

Abstract:
The present invention providesmelflufen (melphalan flufenamide; L-Melphalanyl-4-fluoro-L-phenylalanine ethyl ester), or a salt thereof, for use in the treatment or prophylaxis of multiple myeloma, wherein a dosage of melflufen (excluding the mass of any salt) is administered as a parenteral dosage at an infusion rate of 1.0 to 1.8 mg/min. Also provided is melflufen, or a salt thereof, for use in the treatment or prophylaxis of a cancer, for example a solid cancer, wherein a dosage of melflufen is administered as a parenteral dosage at an infusion rate less than 0.8 mg/min (for example 0.3 to 1.0 mg/minor for example 0.3 to 0.8 mg/min).

Claim (Index 30):
The method as claimed in  claim 22 , wherein the dosage of melflufen is 35 to 45 mg, and/or wherein the dosage is administered over 25 to 35 minutes.

Metadata:
- Claim Count in Document: 53.0
- Percentile: 93.0
- Lexical Diversity: 2.16364
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15241128', '15556183', '15291833', '13708014', '11638193']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7382411341747435
- 35 USC 102 Novelty (BERT): 0.5020719354663941
- Combined Prediction Score: 0.7146242143039085
- Mean Citation Score: 223.139546
- Max Citation Score: 232.19298
- Similarity Product: 158.91440300299288

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test